Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations

Open access

Abstract

(1) Background: Autoantibodies to tumor-associated antigens (TAAs) have emerged as promising cancer biomarkers. Luminex technology offers a powerful approach for the simultaneous detection of multiple anti-TAA autoantibodies. (2) Methods: We aimed to utilize Luminex technology to evaluate and optimize a panel of anti-TAAs autoantibodies for detecting prostate cancer (PCa), which included autoantibodies to fourteen TAAs. A total of 163 serum samples (91 PCa, 72 normal controls) were screened to determine the levels of the autoantibodies using the Luminex assay. (3) Results: Twelve autoantibodies exhibited significantly high frequencies ranging from 19.8% to 51.6% in the PCa group. Receiver operating characteristic (ROC) curve analysis revealed area under the curve (AUC) values ranging from 0.609 to 0.868 for the twelve autoantibodies individually. We further confirmed the performance of the HSP60 autoantibody by using an enzyme-linked immunosorbent assay (ELISA) in a larger sample comprising 200 PCa sera, 20 benign prostatic hyperplasia (BPH) sera, and 137 normal control sera. The results obtained from the Luminex assay were consistent with the ELISA findings. We developed a panel consisting of three autoantibodies (p16, IMP2, and HSP60) which achieved an impressive AUC of 0.910 with a sensitivity of 71.4% and a specificity of 95.8%. The panel was also evaluated in PCa patients from different races/ethnicities with the best performance observed in distinguishing the Hispanic American patients with PCa from normal controls. (4) Conclusions: We developed an anti-TAA autoantibody panel for the detection of PCa that exhibits promising performance. This panel holds significant potential as a high-throughput tool to facilitate PCa detection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15164064

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Median fluorescent intensity (MFI) values of 14 autoantibodies (a–n) in prostate cancer (PCa) group and normal control (NC) group. The MFI values are shown in scatter plots with median and quartiles. ***, p > 0.001; ns, not significant.
Figure 1 Median fluorescent intensity (MFI) values of 14 autoantibodies (a–n) in prostate cancer (PCa) group and normal control (NC) group. The MFI values are shown in scatter plots with median and quartiles. ***, p > 0.001; ns, not significant.CC BY · PubMed Central
Figure 2 ROC analysis of 14 autoantibodies (a–n) in the identification of PCa from normal controls. AUC, area under the curve. The AUC and its 95% confidence interval are shown in the figure for each autoantibody.
Figure 2 ROC analysis of 14 autoantibodies (a–n) in the identification of PCa from normal controls. AUC, area under the curve. The AUC and its 95% confidence interval are shown in the figure for each autoantibody.CC BY · PubMed Central
Figure 3 Performance of the autoantibody to HSP60 in the detection of PCa in ELISA. (a) OD values of autoantibody to HSP60 in PCa, BPH, and NC; (b) prevalence of autoantibody to HSP60 among the three groups; (c) performance of autoantibody to HSP60 for identifying PCa from NC; (d) performance of autoantibody to HSP60 for identifying PCa from BPH. PCa, prostate cancer; NC, normal controls; BPH, benign prostatic hyperplasia; OD, optimal density; Se, sensitivity; Sp: Specificity. ***, p > 0.001. The AUC and its 95% confidence interval are shown in the figure.
Figure 3 Performance of the autoantibody to HSP60 in the detection of PCa in ELISA. (a) OD values of autoantibody to HSP60 in PCa, BPH, and NC; (b) prevalence of autoantibody to HSP60 among the three groups; (c) performance of autoantibody to HSP60 for identifying PCa from NC; (d) performance of autoantibody to HSP60 for identifying PCa from BPH. PCa, prostate cancer; NC, normal controls; BPH, benign prostatic hyperplasia; OD, optimal density; Se, sensitivity; Sp: Specificity. ***, p > 0.001. The AUC and its 95% confidence interval are shown in the figure.CC BY · PubMed Central
Figure 4 Performance of the anti-TAA autoantibody panel (p16, IMP2, and HSP60) in the identification of PCa and the levels of 12 anti-TAA autoantibodies in serial sera before and after surgery. (a) AUC with 95% confidence interval of the anti-TAA autoantibody panel for identifying PCa from NC; (b) performance of the anti-TAA autoantibody panel for identifying PCa patients of three different races from NC (red curve: AA vs. NC, blue dotted curve: CC vs. NC, purple dotted curve: HA vs. NC); (c) frequencies of the anti-TAA autoantibody panel in PCa patients of three different races (different letters A–D above the bars mean a significant difference was observed); (d) the autoantibody trend change in 12 PCa patients before and after surgery (3 to 6 months after radical prostatectomy). The points at both ends of the line represent the MFI value of each anti-TAA autoantibodies. PCa, prostate cancer; NC, normal controls; Se, sensitivity; Sp: specificity; AA, African Americans; CC, Caucasians; HA, Hispanic Americans.
Figure 4 Performance of the anti-TAA autoantibody panel (p16, IMP2, and HSP60) in the identification of PCa and the levels of 12 anti-TAA autoantibodies in serial sera before and after surgery. (a) AUC with 95% confidence interval of the anti-TAA autoantibody panel for identifying PCa from NC; (b) performance of the anti-TAA autoantibody panel for identifying PCa patients of three different races from NC (red curve: AA vs. NC, blue dotted curve: CC vs. NC, purple dotted curve: HA vs. NC); (c) frequencies of the anti-TAA autoantibody panel in PCa patients of three different races (different letters A–D above the bars mean a significant difference was observed); (d) the autoantibody trend change in 12 PCa patients before and after surgery (3 to 6 months after radical prostatectomy). The points at both ends of the line represent the MFI value of each anti-TAA autoantibodies. PCa, prostate cancer; NC, normal controls; Se, sensitivity; Sp: specificity; AA, African Americans; CC, Caucasians; HA, Hispanic Americans.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 9

Metadata

Authors
Qiu, C., Wang, X., Batson, S. A., Wang, B., Casiano, C. A., Francia, G., & Zhang, J.-Y.
Affiliations
  • The University of Texas at El Paso (US)
  • Loma Linda University (US)
  • Department of Biological Sciences & NIH-Sponsored Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA
Corresponding author
Francia, Giulio
Venue
Cancers
Publisher
MDPI AG
Published
2023-08-11
Volume
15
Issue
16
Pages
4064
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4385760156
Cited by
9
References
46
Citations by year
2026: 4 · 2025: 4 · 2024: 1
FWCI
1.65
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes on Minority Health and Health Disparities (NIMHD) (5U54MD007592, 1R21CA280647)
  • NIH/National Cancer Institute (5U54MD007592, 1R21CA280647)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
Keywords
prostate cancer, tumor-associated antigens, autoantibodies, Luminex multiplex assay, autoantibody panel, HSP60, p16, IGF2BP2, tumor markers, racial and ethnic diversity, benign prostatic hyperplasia, cancer detection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations. https://app.cochat.ai/papers/10.3390/cancers15164064
The paper
Qiu, C., Wang, X., Batson, S. A., Wang, B., Casiano, C. A., Francia, G., & Zhang, J.-Y. (2023). A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations. Cancers. https://doi.org/10.3390/cancers15164064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.